Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

This live, virtual symposium will bring together a world-renowned expert in the management of breast cancer with a local community oncologist to discuss the role of next-generation selective estrogen receptor degraders (SERDs) in the treatment of hormone receptor–positive, HER2-negative (HR+/HER2-) breast cancer. In this program, the faculty will review recent clinical updates evaluating SERDs for metastatic HR+/HER2- breast cancer and discuss best practices to implement biomarker testing to guide treatment decisions. Case-based conversations will be included throughout the program to provide clinicians with the key takeaways of all the data. Participants will have the opportunity to reflect on how experts make clinical decisions with regards to initiating and sequencing therapy, as well as best practices in managing adverse events.
Learn More